西格列汀对2型糖尿病患者心血管危险因素的影响

Sitagliptin influence on cardiovascular risk factors in patients with type 2 diabetes mellitus

目的:探讨西格列汀对2型糖尿病患者心血管疾病危险因素的影响。方法:收治新诊断2型糖尿病且近3个月单纯使用二甲双胍血糖控制不佳的患者58例,随机分为试验组和对照组。试验组在二甲双胍基础上加用西格列汀,对照组在二甲双胍基础上加用阿卡波糖。结果:两组CIMT、Hcy、CRP水平均较治疗前下降,试验组较对照组低(P<0.05)。结论:西格列汀降糖效果与阿卡波糖相当,但西格列汀还可以改善2型糖尿病患者CIMT、CRP、Hcy水平,减轻炎性反应,延缓或阻止动脉粥样硬化进展,达到保护糖尿病患者大血管的作用。

Objective:To explore the effect of sitagliptin on the risk factors of cardiovascular disease in patients with type 2 diabetes.Methods:58 patients with newly diagnosed type 2 diabetes with poor control of glycemic with metformin for nearly 3 months were selected.They were randomly divided into the experimental group and the control group.The experimental group were added with sitagliptin on the basis of metformin,and the control group was added with acarbose on the basis of metformin.Results:The level of CIMT,Hcy and CRP in both of the groups were decreased compared with before the treatment,and the experimental group was lower than that of the control group(P<0.05).Conclusion:The effect of sitagliptin on hypoglycemic effect is equivalent to acarbose,but sitagliptin can also improve the level of CIMT,CRP and Hcy in type 2 diabetic patients,alleviate the inflammatory reaction,delay or prevent the progress of atherosclerosis,and protect the great vascular effect of diabetic patients.